Pfizer on Tuesday reported second-quarter results that topped estimates and hiked the low end of its revenue outlook, citing an expected $1.5 billion bump in sales from its non-Covid products. That sales range would still be roughly flat or down slightly compared with 2025 revenue of $62.6 billion. Eliquis in particular blew past estimates for the quarter, raking in $2.43 billion in sales, up 19%. Recently launched and acquired products also delivered $3.2 billion in revenue during the quarter, Guegan said during the call. The first part of that effort is on track to deliver $1.5 billion in savings by the end of 2027.